Status:
COMPLETED
Protein Requirements in Male and Female Endurance Athletes
Lead Sponsor:
University of Toronto
Conditions:
Increased Metabolic Requirement
Healthy
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Protein is an essential macronutrient for post-exercise recovery through its ability to provide the amino acid building blocks that support increased rates of muscle and whole body protein synthesis. ...
Eligibility Criteria
Inclusion
- Healthy endurance trained runners. Total weekly running distance of greater than 50km/week and perform endurance exercise for more than 5 hours/week.
- Age 18-35 years old
- Eumenorrheic over last 3 months (one cycle no longer than 42 days and no shorter than 20 days).
- Not using hormonal contraceptives (the pill, implants and injections, hormonal intrauterine devices (IUDs), vaginal ring, skin patch).
- Do not have polycystic ovarian syndrome (PCOS) or other conditions effecting ovarian hormone regularity.
- Not pregnant within the past year.
- Must meet the classification of 'superior' aerobic power for their respective age category based on the ACSM criteria; (women age 20-29 years VO2max \>50ml/kg/min and women age 30-35 years VO2max \>46ml/kg/min) (men age 20-29 years VO2max \>56ml/kg/min and men age 30-35 years VO2max \>54ml/kg/min).
Exclusion
- Inability to meet health and physical activity guidelines according to the CSEP 'Get Active' Questionnaire (Appendix G).
- Inability to adhere to study protocol requirements relating to diet and exercise (i.e. alcohol and caffeine consumption, training/exercise prior to beginning a study testing day).
- Regular use of tobacco and/or other recreational drugs/banned substances (i.e. growth hormone, testosterone, marijuana).
- Self-reported intentional or unintentional weight loss (past 6 months) or plan to lose weight (\>5-10kg).
- Amenorrhea (self-reported) in the past 3 months.
- Fewer than 6 menstrual cycles per year.
- Answering yes to any questions asked within the COVID-19 screening questionnaire until 14 days of being symptom free and/or having a negative COVID-19 test
Key Trial Info
Start Date :
March 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2022
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT04855474
Start Date
March 8 2021
End Date
December 30 2022
Last Update
July 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Goldring Centre for High Performance Sport
Toronto, Ontario, Canada, M5S2C9